# A Post Marketing Surveillance Study of Equfina Tablet 50 Milligram (mg)

> **NCT05225324** · — · COMPLETED · sponsor: **Eisai Korea Inc.** · enrollment: 702 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Equfina 50 mg

## Key facts

- **NCT ID:** NCT05225324
- **Lead sponsor:** Eisai Korea Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-03
- **Primary completion:** 2025-03-20
- **Final completion:** 2025-03-20
- **Target enrollment:** 702 (ACTUAL)
- **Last updated:** 2025-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05225324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05225324, "A Post Marketing Surveillance Study of Equfina Tablet 50 Milligram (mg)". Retrieved via AI Analytics 2026-06-27 from https://api.ai-analytics.org/clinical/NCT05225324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*